Michelle Felicia Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michelle Felicia Lee has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Yuan Seng Wu
Department of Biomedical Sciences, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Sunway City, Malaysia
7 shared publications - Chit Laa Poh
ALPS Global Holding Berhad, The ICON, East Wing Tower, No. 1, Jalan 1/68F, Off Jalan Tun Razak, Kuala Lumpur 50400, Malaysia
5 shared publications - Mahendran Sekar
School of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya, Selangor, Malaysia
3 shared publications - Neeraj Kumar Fuloria
Faculty of Pharmacy, AIMST University, Bedong, Kedah, Malaysia
3 shared publications - Shivkanya Fuloria
Faculty of Pharmacy, AIMST University, Bedong 08100, Kedah, Malaysia
3 shared publications - Lujin Al Quwatli
Sunway Microbiome Centre, School of Medical and Life Sciences, Sunway University, Subang Jaya, Malaysia
2 shared publications
Latest Publications
- 22 April 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78  (3) , 95
TM4SF1 regulates esophageal squamous cell carcinoma KYSE150 cell phenotypes via miRNA-regulated pathways
TM4SF1, a small transmembrane glycoprotein, has been implicated in tumor progression across multiple cancers. However, its functional and regulatory roles in esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), remain unclear. This study aims to characterize TM4SF1 expression in an ESCC cell line, KYSE150, determine its biological role in tumor cell phenotypes, and profile miRNA changes after TM4SF1 knockdown and perform in silico target or pathway analyses. First, TM4SF1 gene expression was analyzed in the KYSE150 cell line by qRT-PCR. shRNA-mediated TM4SF1 knockdown was applied to the KYSE150 cells, followed by proliferation, migration, and apoptosis assays. MiRNA sequencing followed by bioinformatic analyses predicted microRNAs and potential genes targeting TM4SF1, which also included putative composite pathways and gene ontologies. TM4SF1 gene expression was significantly upregulated in the KYSE150 cells compared to EC109 ESCC and HET1A cells, a normal esophageal epithelial cell. Functional bioassays revealed that TM4SF1 knockdown significantly reduced cell proliferation (MTT and CCK-8 assays) by 46%, while reducing wound closure at 24 h by 30.5% with recovery by 48 h and increased 90% of caspase 3/7 activity. The exploratory sequencing of miRNAs revealed the ten most differentially expressed miRNAs (hsa-miR-6510-3p, hsa-miR-675-5p, hsa-miR-524-5p, hsa-miR-9902, hsa-miR-520f-3p, hsa-miR-3192-5p, hsa-miR-1973, hsa-miR-3614-5p, hsa-miR-501-3p, and hsa-miR-1298-5p), whereas bioinformatic analyses predicted 54 target gene predictions, including TP53, RB1, and ICAM3, and 13 composite pathways that encompassed processes such as apoptosis, cell adhesion, and metabolic regulation. This study provides preliminary and useful insights into the role of TM4SF1 within the KYSE150 ESCC cell-line model and provide a basis for future validation in additional ESCC models, alongside initial investigations into its molecular mechanisms, and underscores the necessity of further validation in diverse cells and models and possible therapeutic implications.
- 22 April 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78  (3) , 95
TM4SF1 regulates esophageal squamous cell carcinoma KYSE150 cell phenotypes via miRNA-regulated pathways
TM4SF1, a small transmembrane glycoprotein, has been implicated in tumor progression across multiple cancers. However, its functional and regulatory roles in esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), remain unclear. This study aims to characterize TM4SF1 expression in an ESCC cell line, KYSE150, determine its biological role in tumor cell phenotypes, and profile miRNA changes after TM4SF1 knockdown and perform in silico target or pathway analyses. First, TM4SF1 gene expression was analyzed in the KYSE150 cell line by qRT-PCR. shRNA-mediated TM4SF1 knockdown was applied to the KYSE150 cells, followed by proliferation, migration, and apoptosis assays. MiRNA sequencing followed by bioinformatic analyses predicted microRNAs and potential genes targeting TM4SF1, which also included putative composite pathways and gene ontologies. TM4SF1 gene expression was significantly upregulated in the KYSE150 cells compared to EC109 ESCC and HET1A cells, a normal esophageal epithelial cell. Functional bioassays revealed that TM4SF1 knockdown significantly reduced cell proliferation (MTT and CCK-8 assays) by 46%, while reducing wound closure at 24 h by 30.5% with recovery by 48 h and increased 90% of caspase 3/7 activity. The exploratory sequencing of miRNAs revealed the ten most differentially expressed miRNAs (hsa-miR-6510-3p, hsa-miR-675-5p, hsa-miR-524-5p, hsa-miR-9902, hsa-miR-520f-3p, hsa-miR-3192-5p, hsa-miR-1973, hsa-miR-3614-5p, hsa-miR-501-3p, and hsa-miR-1298-5p), whereas bioinformatic analyses predicted 54 target gene predictions, including TP53, RB1, and ICAM3, and 13 composite pathways that encompassed processes such as apoptosis, cell adhesion, and metabolic regulation. This study provides preliminary and useful insights into the role of TM4SF1 within the KYSE150 ESCC cell-line model and provide a basis for future validation in additional ESCC models, alongside initial investigations into its molecular mechanisms, and underscores the necessity of further validation in diverse cells and models and possible therapeutic implications.
- 13 April 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78  (3) , 89
Cytotoxicity and potential cell death mechanisms of three new benzamidine derivatives in esophageal squamous cell carcinoma cells using in vitro and in silico approaches
Esophageal cancer remains a significant global health challenge with increasing rates of incidence and mortality, particularly esophageal squamous cell carcinoma (ESCC), with higher prevalence in Asia. This study aims to investigate the cytotoxicity and potential cell death mechanisms (i.e., apoptosis, necroptosis, ferroptosis, and pyroptosis) induced by three newly synthesized benzamidine derivatives (NBDs) against the ESCC KYSE-150 cell line. MTT cell viability assay was used to assess the cytotoxic effect of the NBDs on the ESCC cell line, KYSE-150, and the normal esophageal epithelial cell line, HET-1A. In silico molecular simulation and binding free energy calculation methods were used to validate the potential cell death targets (s) involved in ESCC cells upon interaction with the NBDs. The results showed that the cytotoxic effect of all three NBDs on KYSE-150 outperformed 5-fluorouracil (5-FU), with NBD 3 producing the highest cytotoxicity (IC50: 21.57 ÂľM), followed by NBD 2 (IC50: 34.17 ÂľM) and NBD 1 (IC50: 37.75 ÂľM). Among the three NBDs, NBD 3 was the most potent in inducing cytotoxicity in KYSE-150 cells. In silico molecular docking revealed that NBD 2 and NBD 3 exhibited relatively strong binding affinities (< -7.0 kcal/mol) toward multiple protein targets, including Caspase-9, BIM BH3 peptide, BCL2 Antagonist/Killer (BAK), Tumor Necrosis Factor Receptor (TNFR), Fas Cell Surface Death Receptor (FAS), BCL2-Like 1, long isoform (BCL-XL), BCL2-Like 2 (BCL-W), BCL2-Like 10 (BCL2L10), Heat Shock Protein 70 (Hsp70), Heat Shock Protein 90 (Hsp90), Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1), Dynamin-1-Like Protein (DNM1L), Apoptosis-Inducing Factor, Mitochondria-Associated 2 (AIFM2), and Absent in Melanoma 2 (AIM2), molecular simulation results further confirmed the stability, structural compactness and residual flexibility. In addition, the binding free-energy calculations characterized the relative binding strengths of these derivatives toward the selected pathway targets. These computational results, together with the docking-derived interaction profiles, support the prediction that these programmed cell-death pathways may be potentially engaged in ESCC upon interaction with the NBDs. While the analyses are consistent with possible involvement of these mechanisms, they do not constitute experimental validation and should be interpreted as computational indications rather than confirmatory evidence. This study provides insights into the potential anticancer activities and the mechanistic pathway of NBDs in ESCC. The online version contains supplementary material available at 10.1007/s10616-026-00934-8.
- 13 April 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78  (3) , 89
Cytotoxicity and potential cell death mechanisms of three new benzamidine derivatives in esophageal squamous cell carcinoma cells using in vitro and in silico approaches
Esophageal cancer remains a significant global health challenge with increasing rates of incidence and mortality, particularly esophageal squamous cell carcinoma (ESCC), with higher prevalence in Asia. This study aims to investigate the cytotoxicity and potential cell death mechanisms (i.e., apoptosis, necroptosis, ferroptosis, and pyroptosis) induced by three newly synthesized benzamidine derivatives (NBDs) against the ESCC KYSE-150 cell line. MTT cell viability assay was used to assess the cytotoxic effect of the NBDs on the ESCC cell line, KYSE-150, and the normal esophageal epithelial cell line, HET-1A. In silico molecular simulation and binding free energy calculation methods were used to validate the potential cell death targets (s) involved in ESCC cells upon interaction with the NBDs. The results showed that the cytotoxic effect of all three NBDs on KYSE-150 outperformed 5-fluorouracil (5-FU), with NBD 3 producing the highest cytotoxicity (IC50: 21.57 ÂľM), followed by NBD 2 (IC50: 34.17 ÂľM) and NBD 1 (IC50: 37.75 ÂľM). Among the three NBDs, NBD 3 was the most potent in inducing cytotoxicity in KYSE-150 cells. In silico molecular docking revealed that NBD 2 and NBD 3 exhibited relatively strong binding affinities (< -7.0 kcal/mol) toward multiple protein targets, including Caspase-9, BIM BH3 peptide, BCL2 Antagonist/Killer (BAK), Tumor Necrosis Factor Receptor (TNFR), Fas Cell Surface Death Receptor (FAS), BCL2-Like 1, long isoform (BCL-XL), BCL2-Like 2 (BCL-W), BCL2-Like 10 (BCL2L10), Heat Shock Protein 70 (Hsp70), Heat Shock Protein 90 (Hsp90), Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1), Dynamin-1-Like Protein (DNM1L), Apoptosis-Inducing Factor, Mitochondria-Associated 2 (AIFM2), and Absent in Melanoma 2 (AIM2), molecular simulation results further confirmed the stability, structural compactness and residual flexibility. In addition, the binding free-energy calculations characterized the relative binding strengths of these derivatives toward the selected pathway targets. These computational results, together with the docking-derived interaction profiles, support the prediction that these programmed cell-death pathways may be potentially engaged in ESCC upon interaction with the NBDs. While the analyses are consistent with possible involvement of these mechanisms, they do not constitute experimental validation and should be interpreted as computational indications rather than confirmatory evidence. This study provides insights into the potential anticancer activities and the mechanistic pathway of NBDs in ESCC. The online version contains supplementary material available at 10.1007/s10616-026-00934-8.
- Open Access
- 16 March 2026
- Published by Springer Nature in Discover Public Health
- Vol. 23  (1) , 339
Association between diabetes mellitus and COVID-19 severity in hospitalized adults: A systematic review and meta-analysis
- 16 March 2026
- Published by Springer Nature in Discover Public Health
- Vol. 23  (1) , 339
Open AccessAssociation between diabetes mellitus and COVID-19 severity in hospitalized adults: A systematic review and meta-analysis
- Open Access
Antiviral Strategies Targeting Enteroviruses: Current Advances and Future Directions
Enteroviruses, a diverse genus within the Picornaviridae family, are responsible for a wide range of human infections, including hand, foot, and mouth disease, respiratory disease, aseptic meningitis, encephalitis, myocarditis, and acute flaccid paralysis. Despite their substantial global health burden and the frequent emergence of outbreaks, no specific antiviral therapies are currently approved for clinical use against non-polio enteroviruses. This review provides a comprehensive overview of the current landscape of antiviral strategies targeting enteroviruses, including direct-acting antivirals such as capsid binders, protease inhibitors, and viral RNA polymerase inhibitors. We also examine the potential of host-targeting agents that interfere with virusâhost interactions essential for replication. Emerging strategies such as immunotherapeutic approaches, RNA interference, CRISPR-based antivirals, and peptide-based antivirals are also explored. Furthermore, we address key challenges, including viral diversity, drug resistance, and limitations in preclinical models. By highlighting recent advances and ongoing efforts in antiviral development, this review aims to guide future research and accelerate the discovery of effective therapies against enterovirus infections.
Open AccessAntiviral Strategies Targeting Enteroviruses: Current Advances and Future Directions
Enteroviruses, a diverse genus within the Picornaviridae family, are responsible for a wide range of human infections, including hand, foot, and mouth disease, respiratory disease, aseptic meningitis, encephalitis, myocarditis, and acute flaccid paralysis. Despite their substantial global health burden and the frequent emergence of outbreaks, no specific antiviral therapies are currently approved for clinical use against non-polio enteroviruses. This review provides a comprehensive overview of the current landscape of antiviral strategies targeting enteroviruses, including direct-acting antivirals such as capsid binders, protease inhibitors, and viral RNA polymerase inhibitors. We also examine the potential of host-targeting agents that interfere with virusâhost interactions essential for replication. Emerging strategies such as immunotherapeutic approaches, RNA interference, CRISPR-based antivirals, and peptide-based antivirals are also explored. Furthermore, we address key challenges, including viral diversity, drug resistance, and limitations in preclinical models. By highlighting recent advances and ongoing efforts in antiviral development, this review aims to guide future research and accelerate the discovery of effective therapies against enterovirus infections.
- Open Access
- 15 January 2025
- Published by HH Publisher in Progress In Microbes & Molecular Biology
- Vol. 8  (1)
Unravelling Alpha-Mangostin as a Promising Anticancer Agent: An Overview of Therapeutic Effects, Molecular Mechanisms, and Strategies to Improve Treatment Outcomes
Cancer represents a significant global health concern, contributing to a high number of fatalities in the 21st century, with projections indicating a continuous spike in cancer cases. Although chemotherapy is an established cancer treatment, it is often associated with adverse effects and chemoresistance. Thus, alternative therapies like natural products that can address these limitations of chemotherapy are crucial. Alpha-mangostin (AM), derived from the mangosteen fruit, has widely demonstrated potent anticancer and enhanced chemosensitivity properties by regulating oncogenic signaling pathways, including phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), nuclear factor-ÎşB (NF-ÎşB), and mitogen-activated protein kinase (MAPK) pathways. This review discusses the current anticancer status of AM in preclinical studies and associated molecular mechanisms. It also further identifies the challenges and strategies to enhance the anticancer activity of AM. AM has shown strong anticancer effects in preclinical studies across multiple cancer types, including breast, cervical, ovarian, colorectal, pancreatic, prostate, and lung cancers. It induces apoptosis, causes cell cycle arrest, and inhibits the proliferation of cancer cells. AM also reduces cancer progression and metastasis by targeting key signaling pathways, demonstrating broad therapeutic potential. To overcome the limitations of AM, such as low bioavailability and limited clinical evidence, strategies like nanotechnology, chemical modification, and combination with chemotherapeutic agents have been proposed. These approaches aim to enhance AM's therapeutic potential. However, further research is needed to assess its pharmacokinetics, safety, and clinical efficacy. Future studies should also focus on improving delivery systems and conducting rigorous clinical trials to support AMâs use in integrative cancer therapy. Graphical Alpha-mangostin exerts anticancer effects by regulating cell cycle arrest, inhibiting tumorigenesis, metastasis, and cell proliferation, inducing apoptosis, and enhancing chemosensitivity. However, its therapeutic potential is limited by low solubility, bioavailability, and biodistribution, which could be improved through nanoparticle encapsulation, derivative synthesis, or combination with other chemotherapeutic agents.
- 15 January 2025
- Published by HH Publisher in Progress In Microbes & Molecular Biology
- Vol. 8  (1)
Open AccessUnravelling Alpha-Mangostin as a Promising Anticancer Agent: An Overview of Therapeutic Effects, Molecular Mechanisms, and Strategies to Improve Treatment Outcomes
Cancer represents a significant global health concern, contributing to a high number of fatalities in the 21st century, with projections indicating a continuous spike in cancer cases. Although chemotherapy is an established cancer treatment, it is often associated with adverse effects and chemoresistance. Thus, alternative therapies like natural products that can address these limitations of chemotherapy are crucial. Alpha-mangostin (AM), derived from the mangosteen fruit, has widely demonstrated potent anticancer and enhanced chemosensitivity properties by regulating oncogenic signaling pathways, including phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), nuclear factor-ÎşB (NF-ÎşB), and mitogen-activated protein kinase (MAPK) pathways. This review discusses the current anticancer status of AM in preclinical studies and associated molecular mechanisms. It also further identifies the challenges and strategies to enhance the anticancer activity of AM. AM has shown strong anticancer effects in preclinical studies across multiple cancer types, including breast, cervical, ovarian, colorectal, pancreatic, prostate, and lung cancers. It induces apoptosis, causes cell cycle arrest, and inhibits the proliferation of cancer cells. AM also reduces cancer progression and metastasis by targeting key signaling pathways, demonstrating broad therapeutic potential. To overcome the limitations of AM, such as low bioavailability and limited clinical evidence, strategies like nanotechnology, chemical modification, and combination with chemotherapeutic agents have been proposed. These approaches aim to enhance AM's therapeutic potential. However, further research is needed to assess its pharmacokinetics, safety, and clinical efficacy. Future studies should also focus on improving delivery systems and conducting rigorous clinical trials to support AMâs use in integrative cancer therapy. Graphical Alpha-mangostin exerts anticancer effects by regulating cell cycle arrest, inhibiting tumorigenesis, metastasis, and cell proliferation, inducing apoptosis, and enhancing chemosensitivity. However, its therapeutic potential is limited by low solubility, bioavailability, and biodistribution, which could be improved through nanoparticle encapsulation, derivative synthesis, or combination with other chemotherapeutic agents.
- Open Access
- 15 January 2025
- Published by HH Publisher in Progress In Microbes & Molecular Biology
- Vol. 8  (1)
Anti-Dengue Activity of Revaprazan Hydrochloride: A Repurposed Drug Candidate
Dengue fever is a major health problem, and there are no vaccines or effective antiviral treatments. Drug repurposing is a quick and appealing innovative therapeutic strategy. This study aims to develop a potent anti-dengue drug for the treatment of dengue infections. In this study, we screened a library containing 174 compounds using foci-forming unit reduction and quantitative real-time polymerase chain reaction assays. Revaprazan hydrochloride showed the most potent anti-dengue activity and low cytotoxicity in Vero cells with a half-maximal inhibitory concentration (IC50) of 1.36 Âą 0.16 ÂľM, and a half-maximal cytotoxicity concentration (CC50) of 42.41 Âą 0.05 ÂľM. Revaprazan hydrochloride revealed 98.31% virucidal activity and 99.80% for post-infection activity against dengue virus serotype 3 (DENV-3). Revaprazan hydrochloride required only 5 min to exert its virucidal effects after contact with DENV-3. Time-of-drug addition and time-of-drug elimination assays indicated that revaprazan hydrochloride was able to interfere with the early stage of DENV-3 infection. In silico studies demonstrated that revaprazan hydrochloride had strong binding energy to the RNA-dependent RNA polymerase domain of the NS5 and the helicase domain of the NS2B/NS3 protein. DENV-3 showed no resistance up to 25 passages in the presence of revaprazan hydrochloride. Revaprazan hydrochloride showed varying inhibitory effects against all four dengue virus serotypes. Overall, revaprazan hydrochloride is a novel dengue virus inhibitor and could serve as a promising antiviral drug for further preclinical evaluations.
- 15 January 2025
- Published by HH Publisher in Progress In Microbes & Molecular Biology
- Vol. 8  (1)
Open AccessAnti-Dengue Activity of Revaprazan Hydrochloride: A Repurposed Drug Candidate
Dengue fever is a major health problem, and there are no vaccines or effective antiviral treatments. Drug repurposing is a quick and appealing innovative therapeutic strategy. This study aims to develop a potent anti-dengue drug for the treatment of dengue infections. In this study, we screened a library containing 174 compounds using foci-forming unit reduction and quantitative real-time polymerase chain reaction assays. Revaprazan hydrochloride showed the most potent anti-dengue activity and low cytotoxicity in Vero cells with a half-maximal inhibitory concentration (IC50) of 1.36 Âą 0.16 ÂľM, and a half-maximal cytotoxicity concentration (CC50) of 42.41 Âą 0.05 ÂľM. Revaprazan hydrochloride revealed 98.31% virucidal activity and 99.80% for post-infection activity against dengue virus serotype 3 (DENV-3). Revaprazan hydrochloride required only 5 min to exert its virucidal effects after contact with DENV-3. Time-of-drug addition and time-of-drug elimination assays indicated that revaprazan hydrochloride was able to interfere with the early stage of DENV-3 infection. In silico studies demonstrated that revaprazan hydrochloride had strong binding energy to the RNA-dependent RNA polymerase domain of the NS5 and the helicase domain of the NS2B/NS3 protein. DENV-3 showed no resistance up to 25 passages in the presence of revaprazan hydrochloride. Revaprazan hydrochloride showed varying inhibitory effects against all four dengue virus serotypes. Overall, revaprazan hydrochloride is a novel dengue virus inhibitor and could serve as a promising antiviral drug for further preclinical evaluations.
- 17 December 2024
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 35  (1) , 201-213
Embelin Inhibits Dengue Virus Serotype 2 Infectivity with Nonstructural Protein Helicase as a Potential Molecular Target
- 17 December 2024
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 35  (1) , 201-213
Embelin Inhibits Dengue Virus Serotype 2 Infectivity with Nonstructural Protein Helicase as a Potential Molecular Target
- 10 January 2024
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34  (3) , 609-617
Antiviral Activity of Withanolide A Against Different Infectivity Phases of Dengue Virus Serotype 2 in Vero Cell Line
- 10 January 2024
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34  (3) , 609-617
Antiviral Activity of Withanolide A Against Different Infectivity Phases of Dengue Virus Serotype 2 in Vero Cell Line
- 14 December 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113  (3) , 587-595
Serum Stabilities and Antiviral Activities of Chemically Modified Peptides Against Dengue Serotypes 1â4
- 14 December 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113  (3) , 587-595
Serum Stabilities and Antiviral Activities of Chemically Modified Peptides Against Dengue Serotypes 1â4
- Top Cited PapersOpen Access
Molecular Mechanisms of Antiviral Agents against Dengue Virus
Dengue is a major global health threat causing 390 million dengue infections and 25,000 deaths annually. The lack of efficacy of the licensed Dengvaxia vaccine and the absence of a clinically approved antiviral against dengue virus (DENV) drive the urgent demand for the development of novel anti-DENV therapeutics. Various antiviral agents have been developed and investigated for their anti-DENV activities. This review discusses the mechanisms of action employed by various antiviral agents against DENV. The development of host-directed antivirals targeting host receptors and direct-acting antivirals targeting DENV structural and non-structural proteins are reviewed. In addition, the development of antivirals that target different stages during post-infection such as viral replication, viral maturation, and viral assembly are reviewed. Antiviral agents designed based on these molecular mechanisms of action could lead to the discovery and development of novel anti-DENV therapeutics for the treatment of dengue infections. Evaluations of combinations of antiviral drugs with different mechanisms of action could also lead to the development of synergistic drug combinations for the treatment of dengue at any stage of the infection.
Top Cited PapersOpen AccessMolecular Mechanisms of Antiviral Agents against Dengue Virus
Dengue is a major global health threat causing 390 million dengue infections and 25,000 deaths annually. The lack of efficacy of the licensed Dengvaxia vaccine and the absence of a clinically approved antiviral against dengue virus (DENV) drive the urgent demand for the development of novel anti-DENV therapeutics. Various antiviral agents have been developed and investigated for their anti-DENV activities. This review discusses the mechanisms of action employed by various antiviral agents against DENV. The development of host-directed antivirals targeting host receptors and direct-acting antivirals targeting DENV structural and non-structural proteins are reviewed. In addition, the development of antivirals that target different stages during post-infection such as viral replication, viral maturation, and viral assembly are reviewed. Antiviral agents designed based on these molecular mechanisms of action could lead to the discovery and development of novel anti-DENV therapeutics for the treatment of dengue infections. Evaluations of combinations of antiviral drugs with different mechanisms of action could also lead to the development of synergistic drug combinations for the treatment of dengue at any stage of the infection.